TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 4, 2015, details the results of the annual meeting of stockholders held on that date. The meeting took place at the offices of Alston & Bird LLP in New York, New York.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders representing 39,596,852 shares (82.90% of shares entitled to vote) were present. All three proposals submitted were approved:
- Proposal 1 (Election of Directors): Seven directors were elected to serve until the 2016 annual meeting: Michael S. Weiss, Laurence N. Charney, William J. Kennedy, Mark Schoenebaum, MD, Yann Echelard, Kenneth Hoberman, and Daniel Hume. Kenneth Hoberman was appointed Chair of the Compensation Committee, and Laurence N. Charney was appointed Chair of the Audit Committee.
- Proposal 2 (Ratification of Auditors): CohnReznick LLP was approved as the independent registered public accountant for the fiscal year ending December 31, 2015.
- Proposal 3 (Incentive Plan Amendment): An amendment to the Company's 2012 Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It serves strictly as a report of the shareholder vote outcomes.
Key Facts for Investor Verification
- Verify the composition of the new Board of Directors and committee assignments effective immediately following the June 4, 2015 meeting.
- Confirm the ratification of CohnReznick LLP as the auditor for the 2015 fiscal year.
- Review the specific terms of the amendment to the 2012 Incentive Plan as detailed in the definitive proxy statement dated April 24, 2015.
- Note that the filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.